Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages
Interleukin-10 (IL-10), a potent antiinflammatory and immunosuppressive cytokine, plays an important role in the regulation of immune responses. To discover small molecules that stimulate IL-10 production, a cell-based screening assay was performed using a murine macrophage cell line, RAW264.7. Imid...
Gespeichert in:
| Veröffentlicht in: | Biochemical and biophysical research communications 2003-09, Vol.309 (2), p.414-418 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 418 |
|---|---|
| container_issue | 2 |
| container_start_page | 414 |
| container_title | Biochemical and biophysical research communications |
| container_volume | 309 |
| creator | Katayama, Toyoko Hayashi, Yasuhiro Nagahira, Kazuhiro Konishi, Kyoko Yamaichi, Kozo Oikawa, Shinzo |
| description | Interleukin-10 (IL-10), a potent antiinflammatory and immunosuppressive cytokine, plays an important role in the regulation of immune responses. To discover small molecules that stimulate IL-10 production, a cell-based screening assay was performed using a murine macrophage cell line, RAW264.7. Imidocarb, (3,3
′-bis-2-imidazolin-2-yl)-carbanilide, which has been used as an anti-protozoan drug for the prevention and treatment of babesiosis in cattle, was thus identified. Imidocarb markedly enhanced LPS-induced IL-10 production not only by RAW264.7 cells but also by murine peritoneal macrophages in a concentration-dependent manner. It also augmented IL-10 production in the presence of zymosan, a yeast cell wall component. In contrast, imidocarb inhibited LPS-induced tumor necrosis factor (TNF)-α production by peritoneal macrophages. In mice, intraperitoneal administration of imidocarb significantly increased serum IL-10 levels and lowered TNF-α levels. Our results suggest that a novel anti-inflammatory property of imidocarb could lead to new therapeutic approaches in inflammatory conditions. |
| doi_str_mv | 10.1016/j.bbrc.2003.08.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73609096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X03016073</els_id><sourcerecordid>73609096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-d370b17d2963daaa1d3c273e2c4a7fcf10208d4f95a318e97e52bb69e28f6c953</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6BzxITp6226qkvwJeZNnVhQUvu-AtpJPqMWN_maSF9debYQa86akuTz1UvS9jbxFKBGw-HMq-D7YUALKErgRsn7EdgoJCIFTP2Q4AmkIo_HbBXsV4AECsGvWSXaBQNUJT7xjdTd4t1oT-ihu-LonmxM2cfLGGJS2_FzNzF7b9Fd_WItB-G02iyP2cKIy0_fBzgcAz6zab_DLz_olPW_Az8cnYsKzfzZ7ia_ZiMGOkN-d5yR5vbx6uvxT3Xz_fXX-6L6zsZCqcbKHH1gnVSGeMQSetaCUJW5l2sAOCgM5Vg6qNxI5US7Xo-0aR6IbGqlpesvcnbz7o50Yx6clHS-NoZlq2qFvZ5Hiy_X8gqg6lqjCD4gTmX2IMNOg1-MmEJ42gjy3ogz62oI8taOh0biEvvTvbt34i93flHHsGPp4AymH88hR0tJ5mS84Hskm7xf_L_wfFbpmo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19813941</pqid></control><display><type>article</type><title>Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Katayama, Toyoko ; Hayashi, Yasuhiro ; Nagahira, Kazuhiro ; Konishi, Kyoko ; Yamaichi, Kozo ; Oikawa, Shinzo</creator><creatorcontrib>Katayama, Toyoko ; Hayashi, Yasuhiro ; Nagahira, Kazuhiro ; Konishi, Kyoko ; Yamaichi, Kozo ; Oikawa, Shinzo</creatorcontrib><description>Interleukin-10 (IL-10), a potent antiinflammatory and immunosuppressive cytokine, plays an important role in the regulation of immune responses. To discover small molecules that stimulate IL-10 production, a cell-based screening assay was performed using a murine macrophage cell line, RAW264.7. Imidocarb, (3,3
′-bis-2-imidazolin-2-yl)-carbanilide, which has been used as an anti-protozoan drug for the prevention and treatment of babesiosis in cattle, was thus identified. Imidocarb markedly enhanced LPS-induced IL-10 production not only by RAW264.7 cells but also by murine peritoneal macrophages in a concentration-dependent manner. It also augmented IL-10 production in the presence of zymosan, a yeast cell wall component. In contrast, imidocarb inhibited LPS-induced tumor necrosis factor (TNF)-α production by peritoneal macrophages. In mice, intraperitoneal administration of imidocarb significantly increased serum IL-10 levels and lowered TNF-α levels. Our results suggest that a novel anti-inflammatory property of imidocarb could lead to new therapeutic approaches in inflammatory conditions.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2003.08.017</identifier><identifier>PMID: 12951065</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antiprotozoal Agents - pharmacology ; Cell Line ; Dose-Response Relationship, Drug ; Female ; IL-10 ; Imidocarb ; Imidocarb - pharmacology ; Inflammation ; Interleukin-10 - biosynthesis ; Interleukin-10 - blood ; Lipopolysaccharides - pharmacology ; LPS ; Macrophages ; Macrophages - drug effects ; Macrophages - metabolism ; Mice ; Mice, Inbred BALB C ; TNF-α ; Up-Regulation - drug effects ; Zymosan - pharmacology</subject><ispartof>Biochemical and biophysical research communications, 2003-09, Vol.309 (2), p.414-418</ispartof><rights>2003 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-d370b17d2963daaa1d3c273e2c4a7fcf10208d4f95a318e97e52bb69e28f6c953</citedby><cites>FETCH-LOGICAL-c383t-d370b17d2963daaa1d3c273e2c4a7fcf10208d4f95a318e97e52bb69e28f6c953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006291X03016073$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12951065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katayama, Toyoko</creatorcontrib><creatorcontrib>Hayashi, Yasuhiro</creatorcontrib><creatorcontrib>Nagahira, Kazuhiro</creatorcontrib><creatorcontrib>Konishi, Kyoko</creatorcontrib><creatorcontrib>Yamaichi, Kozo</creatorcontrib><creatorcontrib>Oikawa, Shinzo</creatorcontrib><title>Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>Interleukin-10 (IL-10), a potent antiinflammatory and immunosuppressive cytokine, plays an important role in the regulation of immune responses. To discover small molecules that stimulate IL-10 production, a cell-based screening assay was performed using a murine macrophage cell line, RAW264.7. Imidocarb, (3,3
′-bis-2-imidazolin-2-yl)-carbanilide, which has been used as an anti-protozoan drug for the prevention and treatment of babesiosis in cattle, was thus identified. Imidocarb markedly enhanced LPS-induced IL-10 production not only by RAW264.7 cells but also by murine peritoneal macrophages in a concentration-dependent manner. It also augmented IL-10 production in the presence of zymosan, a yeast cell wall component. In contrast, imidocarb inhibited LPS-induced tumor necrosis factor (TNF)-α production by peritoneal macrophages. In mice, intraperitoneal administration of imidocarb significantly increased serum IL-10 levels and lowered TNF-α levels. Our results suggest that a novel anti-inflammatory property of imidocarb could lead to new therapeutic approaches in inflammatory conditions.</description><subject>Animals</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Cell Line</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>IL-10</subject><subject>Imidocarb</subject><subject>Imidocarb - pharmacology</subject><subject>Inflammation</subject><subject>Interleukin-10 - biosynthesis</subject><subject>Interleukin-10 - blood</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>LPS</subject><subject>Macrophages</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>TNF-α</subject><subject>Up-Regulation - drug effects</subject><subject>Zymosan - pharmacology</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7rj6BzxITp6226qkvwJeZNnVhQUvu-AtpJPqMWN_maSF9debYQa86akuTz1UvS9jbxFKBGw-HMq-D7YUALKErgRsn7EdgoJCIFTP2Q4AmkIo_HbBXsV4AECsGvWSXaBQNUJT7xjdTd4t1oT-ihu-LonmxM2cfLGGJS2_FzNzF7b9Fd_WItB-G02iyP2cKIy0_fBzgcAz6zab_DLz_olPW_Az8cnYsKzfzZ7ia_ZiMGOkN-d5yR5vbx6uvxT3Xz_fXX-6L6zsZCqcbKHH1gnVSGeMQSetaCUJW5l2sAOCgM5Vg6qNxI5US7Xo-0aR6IbGqlpesvcnbz7o50Yx6clHS-NoZlq2qFvZ5Hiy_X8gqg6lqjCD4gTmX2IMNOg1-MmEJ42gjy3ogz62oI8taOh0biEvvTvbt34i93flHHsGPp4AymH88hR0tJ5mS84Hskm7xf_L_wfFbpmo</recordid><startdate>20030919</startdate><enddate>20030919</enddate><creator>Katayama, Toyoko</creator><creator>Hayashi, Yasuhiro</creator><creator>Nagahira, Kazuhiro</creator><creator>Konishi, Kyoko</creator><creator>Yamaichi, Kozo</creator><creator>Oikawa, Shinzo</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20030919</creationdate><title>Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages</title><author>Katayama, Toyoko ; Hayashi, Yasuhiro ; Nagahira, Kazuhiro ; Konishi, Kyoko ; Yamaichi, Kozo ; Oikawa, Shinzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-d370b17d2963daaa1d3c273e2c4a7fcf10208d4f95a318e97e52bb69e28f6c953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Cell Line</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>IL-10</topic><topic>Imidocarb</topic><topic>Imidocarb - pharmacology</topic><topic>Inflammation</topic><topic>Interleukin-10 - biosynthesis</topic><topic>Interleukin-10 - blood</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>LPS</topic><topic>Macrophages</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>TNF-α</topic><topic>Up-Regulation - drug effects</topic><topic>Zymosan - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katayama, Toyoko</creatorcontrib><creatorcontrib>Hayashi, Yasuhiro</creatorcontrib><creatorcontrib>Nagahira, Kazuhiro</creatorcontrib><creatorcontrib>Konishi, Kyoko</creatorcontrib><creatorcontrib>Yamaichi, Kozo</creatorcontrib><creatorcontrib>Oikawa, Shinzo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katayama, Toyoko</au><au>Hayashi, Yasuhiro</au><au>Nagahira, Kazuhiro</au><au>Konishi, Kyoko</au><au>Yamaichi, Kozo</au><au>Oikawa, Shinzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2003-09-19</date><risdate>2003</risdate><volume>309</volume><issue>2</issue><spage>414</spage><epage>418</epage><pages>414-418</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>Interleukin-10 (IL-10), a potent antiinflammatory and immunosuppressive cytokine, plays an important role in the regulation of immune responses. To discover small molecules that stimulate IL-10 production, a cell-based screening assay was performed using a murine macrophage cell line, RAW264.7. Imidocarb, (3,3
′-bis-2-imidazolin-2-yl)-carbanilide, which has been used as an anti-protozoan drug for the prevention and treatment of babesiosis in cattle, was thus identified. Imidocarb markedly enhanced LPS-induced IL-10 production not only by RAW264.7 cells but also by murine peritoneal macrophages in a concentration-dependent manner. It also augmented IL-10 production in the presence of zymosan, a yeast cell wall component. In contrast, imidocarb inhibited LPS-induced tumor necrosis factor (TNF)-α production by peritoneal macrophages. In mice, intraperitoneal administration of imidocarb significantly increased serum IL-10 levels and lowered TNF-α levels. Our results suggest that a novel anti-inflammatory property of imidocarb could lead to new therapeutic approaches in inflammatory conditions.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>12951065</pmid><doi>10.1016/j.bbrc.2003.08.017</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-291X |
| ispartof | Biochemical and biophysical research communications, 2003-09, Vol.309 (2), p.414-418 |
| issn | 0006-291X 1090-2104 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73609096 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antiprotozoal Agents - pharmacology Cell Line Dose-Response Relationship, Drug Female IL-10 Imidocarb Imidocarb - pharmacology Inflammation Interleukin-10 - biosynthesis Interleukin-10 - blood Lipopolysaccharides - pharmacology LPS Macrophages Macrophages - drug effects Macrophages - metabolism Mice Mice, Inbred BALB C TNF-α Up-Regulation - drug effects Zymosan - pharmacology |
| title | Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A33%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imidocarb,%20a%20potent%20anti-protozoan%20drug,%20up-regulates%20interleukin-10%20production%20by%20murine%20macrophages&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Katayama,%20Toyoko&rft.date=2003-09-19&rft.volume=309&rft.issue=2&rft.spage=414&rft.epage=418&rft.pages=414-418&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2003.08.017&rft_dat=%3Cproquest_cross%3E73609096%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19813941&rft_id=info:pmid/12951065&rft_els_id=S0006291X03016073&rfr_iscdi=true |